ArticleAnnals of nuclear medicine2026
Impact of biguanide therapy on hepatic
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivePrevious studies have shown that patient characteristics, such as fasting blood glucose, can modulate hepatic
methodsThis retrospective study included 107 patients with diabetes who underwent dynamic whole-body FDG-PET/CT after a 4-h fast and drug withdrawal between January 2022 and May 2025. Patients with hepatic structural abnormalities or artifacts were excluded. PET kinetic parameters (SULmean, Ki, and DV) were measured in the liver and analyzed for associations with clinical variables, including biguanide and insulin therapy, via multivariate regression.
resultsAmong the 107 patients included, 44 and 9 received biguanide and insulin, respectively. Multivariate regression showed that biguanide therapy, but not insulin use or other clinical variables, was significantly associated with increased hepatic SULmean (p = 0.037). No clinical variables were significantly associated with Ki or DV in the corresponding models. These findings suggest that biguanide therapy elevates static hepatic FDG uptake, whereas hepatic glucose metabolic dynamics, as assessed by Ki and DV, did not show significant alterations associated with the antidiabetic medications evaluated in our cohort under standard pre-scan preparation.
conclusionsOur study demonstrates that biguanide therapy increases static hepatic FDG accumulation without interfering with the underlying glucose metabolic dynamics (Ki and DV). The observed increase in SULmean is numerically significant but visually minimal; thus, its impact on routine diagnostic interpretation is likely minimal.
Indexed as
Identifiers
42366327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.